

# THE LANCET

## Child & Adolescent Health

### **Supplementary appendix**

This appendix formed part of the original submission and has been peer reviewed.  
We post it as supplied by the authors.

Supplement to: Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S.  
Post-acute COVID-19 outcomes in children with mild and asymptomatic disease.  
*Lancet Child Adolesc Health* 2021; published online April 20. [http://dx.doi.org/10.1016/S2352-4642\(21\)00124-3](http://dx.doi.org/10.1016/S2352-4642(21)00124-3).

## **Appendix 1 COVID-19 Follow-up Clinic Proforma**

### **DEMOGRAPHICS**

Name

Hospital UR number

Date of Birth

Visit Date

Months following COVID-19

### **TIMELINE**

Last exposure to COVID-19 date + location

Onset of symptoms date

Resolution of symptoms date

Positive swab (s) date/results

Serology date/results

### **ACUTE SYMPTOMS (day 0-14)**

Fever >38

Sore throat

Cough

Runny nose

Shortness of breath

Loss of taste

Loss of smell

Poor appetite

Vomiting

Low energy or tiredness

Headaches

Muscle aches and pains

Abdominal pain

Diarrhoea

Other

### **POST-ACUTE SYMPTOMS (day 14 onwards)**

*Above symptoms plus following:*

Shortness of breath

Fatigue

Rash

Fever

Abdominal pain

Conjunctivitis

Wellbeing

Immunisation Reaction

Other

### **MEDICAL MANAGEMENT**

Readmission to hospital

Review by GP

Review for testing

Other

### **RISK FACTORS**

Travel

Childcare/school confirmed contact

Confirmed household contact  
Unknown  
Other

**HOUSEHOLD MEMBERS AND STATUS**

*Symptomatic/tested/date*

**HEALTH CARE WORKER IN HOUSEHOLD**

*Symptomatic/tested/date/location of work*

**CHILDCARE/SCHOOL NAME**

**IMMUNISATION STATUS:**

Up to date  
Flu vaccine

**PAST MEDICAL HISTORY**

**INVESTIGATIONS**

Antibody results

**PHYSICAL EXAMINATION**

*Weight/height/findings*

**ANY PARENTAL CONCERNS**

## Appendix 2. Patient and Clinical Characteristics of Overall Cohort

Patient and Clinical Characteristics n = 171	
Gender	n (%)
Male	90 (53%)
Female	81 (47%)
Age	
Mean	5 years
Median	3 years
Interquartile range	1-8 years
0-2 years	76 (44%)
3-5 years	37 (22%)
6-12 years	38 (22%)
13-18 years	20 (12%)
Comorbidities	
Total with comorbidities	24 (14%)
Congenital cardiac disease	3 (2%)
Malignancy	1 (1%)
Prematurity	2 (1%)
Immunocompromised <sup>a</sup>	10 (6%)
Chronic respiratory condition	8 (5%)
Symptom duration	
Mean	7.1 days
Median	5 days
Interquartile range	2-9 days
Acute disease severity	
Asymptomatic	61 (36%)
Mild disease	100 (58%)
Moderate disease	9 (5%)
Severe disease	1 (1%)
Reason for hospital admission	
Total admitted	14 (8%)
Observation	7 (4%)
Fluid rehydration	3 (2%)
Unrelated admission <sup>b</sup>	3 (2%)
Intensive care requirement	1 (1%)

<sup>a</sup>Chronic medical condition or medication resulting in immunocompromise

<sup>b</sup>Incidental diagnosis of COVID-19 during admission for an unrelated issue